<DOC>
	<DOCNO>NCT00693667</DOCNO>
	<brief_summary>The primary objective clinical study evaluate effectiveness safety PH3 prevention osteoporosis . The secondary objective identify optimal dosage subsequent study provide basis next confirmatory study study design , endpoint , study methodology .</brief_summary>
	<brief_title>Study PH3 Prevention Osteoporosis Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>1 . Women 4060 year age . 2 . Must postmenopausal ( 0.5~5 year post cessation menses ) ovariectomized hysterectomy woman document elevated Follicle Stimulating Hormone FSH ( &gt; 30mIU/ml ) low serum estradiol ( &lt; 20 pg/ml ) . 3 . The lumbar vertebral BMD Tscore 1and 2.5 SD . 4 . The body mass index ( BMI ) 19 29 kg/m2 . 5 . Completed informed consent sign informed consent form . 1 . Have disease may affect bone metabolism , e. g. , hyperor hypocalcemia , hyperthyroidism , osteogenesis imperfecta , malignancy , chronic gastrointestinal disease , extensive Paget 's disease , alcoholism , renal hepatic impairment . 2 . Has take drug therapy osteoporosis within previous six month ( exclude calcium supplement ) prior study . 3 . Chronic continue use hormone replacement drug medication may affect bone calcium metabolism , example , phosphatebinding antacid , many diuretic , adrenal anabolic steroid , heparin , anticonvulsant , fluoride excess 1 mg/day supplement vitamin D A excess RDAs . 4 . Vitamin D deficiency ( 1 , 25dihydroxyvitamin D low normal range : 25.1 pg/mL ~ 66.1 pg/mL ) . 5 . Patients fracture history . 6 . Patients promise keep take stimulant drink ( example , coffee , tea , alcoholic drink , Coke ) may cause loss bone calcium , study period .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal woman</keyword>
	<keyword>botanical drug</keyword>
</DOC>